Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer

DNA Repair

Volumn 23, Issue , 2014, Pages 79-87

  Santidrian, Antonio F ^a   LeBoeuf, Sarah E ^a   Wold, Erik D ^a   Ritland, Melissa ^a   Forsyth, Jane S ^a   Felding, Brunhilde H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; Integrins; Metastasis; NAD+ salvage pathway; NAMPT; v 3

Indexed keywords

BETA1 INTEGRIN; INTEGRIN; LENTIVIRUS VECTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SCLEROPROTEIN; VITRONECTIN RECEPTOR; CYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; VITRONECTIN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENICITY; CELL ADHESION; CELL ADHESION ASSAY; DNA REPAIR; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOUSE; NONHUMAN; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD29; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRIN ALPHAVBETA3; MICE, SCID; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; VITRONECTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84917696252     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2014.08.006     Document Type: Article

References (66)

1. Chiarugi A., Dölle C., Felici R., Ziegler M. The NAD metabolome - a key determinant of cancer cell biology. Nat. Rev. Cancer 2012, 12:1-12.
2. Xu P., Sauve A.A. Vitamin B3, the nicotinamide adenine dinucleotides and aging. Mech. Ageing Dev. 2010, 131:287-298.
3. + metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity. BMC Chem. Biol. 2010, 10(2).
4. + precursor vitamins in human nutrition. Annu. Rev. Nutr. 2008, 28:115-130.
5. Imai S., Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes. Metab. 2013, 15(Suppl. 3):26-33.
6. Kirkland J.B. Niacin status, NAD distribution and ADP-ribose metabolism. Curr. Pharm. Des. 2009, 15:3-11.
7. +/NADH balance regulate breast cancer progression. J. Clin. Invest. 2013, 3.
8. + synthesis. Cell 2007, 129:453-454.
9. Feldman J.L., Dittenhafer-Reed K.E., Denu J.M. Sirtuin catalysis and regulation. J. Biol. Chem. 2012, 287:42419-42427.
10. Gallí M., Van Gool F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010, 70:8-11.
11. Galli U., et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem. 2013, 56:6279-6296.
12. Garten A., Petzold S., Körner A., Imai S.-I., Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 2009, 20:130-138.
13. Bergamaschi A., et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes. Chromosomes Cancer 2006, 45:1033-1040.
14. Sato T., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res. 1991, 51:5794-5799.
15. Fang M., et al. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis. Cancer 2011, 117:2024-2034.
16. Loo L.W.M., et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004, 64:8541-8549.
17. Morton R.K. Enzymic synthesis of coenzyme I in relation to chemical control of cell growth. Nature 1958, 181:540-542.
18. Branster M.V., Morton R. Comparative rates of synthesis in diphosphopyridine nucleotide by normal and tumour tissue from mouse mammary gland: studies with isolated nuclei. Biochem. J. 1956, 63:640.
19. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
20. Bajrami I., et al. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol. Med. 2012, 4:1087-1096.
21. Hsu C.P., Hariharan N., Alcendor R.R., Oka S., Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through autophagy in cardiomyocytes. Autophagy 2009, 5:1229-1231.
22. Hasmann M., Schemainda I.F.K866 a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63:7436-7442.
23. Wang B., et al. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2011, 30:907-921.
24. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin. Exp. Metastasis 2003, 20:203-213.
25. Hynes R.O. The emergence of integrins: a personal and historical perspective. Matrix Biol. 2004, 23:333-340.
26. Felding-Habermann B., et al. Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17210-17215.
27. Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 1982, 156:1755-1766.
28. Bowditch R.D., et al. Identification of a novel integrin binding site in fibronectin. Differential utilization by beta 3 integrins. J. Biol. Chem. 1994, 269:10856-10863.
29. Wayner E.A., Orlando R.A., Cheresh D.A. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 1991, 113:919-929.
30. Goodwin A.E., Pauli B.U. A new adhesion assay using buoyancy to remove non-adherent cells. J. Immunol. Methods 1995, 187:213-219.
31. Pilch J., Habermann R., Felding-Habermann B. Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J. Biol. Chem. 2002, 277:21930-21938.
32. Wong N.C., et al. Alphav integrins mediate adhesion and migration of breast carcinoma cell lines. Clin. Exp. Metastasis 1998, 16:50-61.
33. Lundström A., Holmbom J., Lindqvist C., Nordström T. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem. Biophys. Res. Commun. 1998, 250:735-740.
34. Denda S., Müller U., Crossin K.L., Erickson H.P., Reichardt L.F. Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin alpha 8 beta 1 receptor interactions with tenascin: murine alpha 8 beta 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C. Biochemistry 1998, 37:5464-5474.
35. Ginsberg M.H., Partridge A., Shattil S.J. Integrin regulation. Curr. Opin. Cell Biol. 2005, 17:509-516.
36. Liddington R.C., Ginsberg M.H. Integrin activation takes shape. J. Cell Biol. 2002, 158:833-839.
37. Johansson M.W., Mosher D.F. Integrin activation states and eosinophil recruitment in asthma. Front. Pharmacol. 2013, 4:33.
38. Felding-Habermann B., et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1853-1858.
39. Ferguson M.A., Williams A.F. Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu. Rev. Biochem. 1988, 57:285-320.
40. +-dependent signalling. FEBS Lett. 2011, 585:1651-1656.
41. Valenzuela M.T., et al. PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21:1108-1116.
42. Vaziri H., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
43. Sauve A.A., Youn D.Y. Sirtuins: NAD(+)-dependent deacetylase mechanism and regulation. Curr. Opin. Chem. Biol. 2012, 16:535-543.
44. + modulates p53 DNA binding specificity and function. Mol. Cell. Biol. 2004, 24:9958-9967.
45. Deng Y., et al. Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. Oncogene 2010, 29:6603-6608.
46. Di L.-J., Fernandez A.G., De Siervi A., Longo D.L., Gardner K. Transcriptional regulation of BRCA1 expression by a metabolic switch. Nat. Struct. Mol. Biol. 2010, 17:1406-1413.
47. Tripathi M.K., et al. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J. Biol. Chem. 2005, 280:17163-17171.
48. Lee Y.-C., et al. High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1892-1901.
49. Shackelford R.E., Mayhall K., Maxwell N.M., Kandil E., Coppola D. Nicotinamide phosphoribosyltransferase in malignancy: a review. Genes Cancer 2013, 4:447-456.
50. Folgueira M.A.A.K., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 2005, 11:7434-7443.
51. Von Wnuck Lipinski K., et al. Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen. Circ. Res. 2006, 98:1490-1497.
52. Wu Y., et al. Kininostatin associates with membrane rafts and inhibits alpha(v)beta3 integrin activation in human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1968-1975.
53. Margheri F., et al. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget 2014, 5:1538-1553.
54. Van Horssen R., et al. Intracellular NAD(H) levels control motility and invasion of glioma cells. Cell. Mol. Life Sci. 2013, 70:2175-2190.
55. + in fungi and humans. Cell 2004, 117:495-502.
56. Lorger M., Krueger J.S., O'Neal M., Staflin K., Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10666-10671.
57. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11:123-134.
58. Staflin K., et al. Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin. Exp. Metastasis 2010, 27:217-231.
59. Zhao Z., Gruszczynska-Biegala J., Zolkiewska A. ADP-ribosylation of integrin alpha7 modulates the binding of integrin alpha7beta1 to laminin. Biochem. J. 2005, 385:309-317.
60. Bi T., Che X. Nampt/PBEF/visfatin and cancer. Cancer Biol. Ther. 2010, 10:119-125.
61. Moschen A.R., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 2007, 178:1748-1758.
62. + salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012, 120:3519-3529.
63. Adya R., Tan B.K., Punn A., Chen J., Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 2008, 78:356-365.
64. Li Y., et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008, 283:34833-34843.
65. Chen R., Alvero A.B., Silasi D.-A., Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am. J. Reprod. Immunol. 2007, 57:93-107.
66. Jacques C., et al. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. J. Biol. Chem. 2012, 287:15100-15108.